Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.0300 (6.79%) ($5.0300 - $5.0300) on Mon. Jan. 25, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.79% (three month average) | RSI | 67 | Latest Price | $5.0300(6.79%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 2.4% a day on average for past five trading days. | Weekly Trend | ADMS advances 0.7% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) VCSH(34%) BND(27%) BWX(26%) VCIT(25%) BNDX(21%) | Factors Impacting ADMS price | ADMS will decline at least -1.895% in a week (0% probabilities). XOP(-21%) VXX(-20%) UUP(-20%) XLE(-18%) OIH(-18%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.895% (StdDev 3.79%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $4.67(7.71%) | 10 Day Moving Average | $4.61(9.11%) | 20 Day Moving Average | $4.56(10.31%) | To recent high | -2.3% | To recent low | 0.6% | Market Cap | $142m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |